Piramal Pharma ESG Rating Improves to 64 for FY25

Piramal Pharma's ESG rating improved to 64 for FY 2024-25 from 61, assigned by NSE Sustainability based on public data.
The rating was voluntarily prepared by NSE Sustainability without company engagement, disclosed under SEBI Listing Regulations.
This regulatory filing highlights Piramal Pharma's improved ESG performance and compliance with sustainability reporting.